|
시장보고서
상품코드
1588299
골격 이형성증 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 치료별, 증상별, 지역별, 부문별 예측(2025-2030년)Skeletal Dysplasia Market Size, Share & Trends Analysis Report By Type (Achondroplasia, X-linked Hypophosphatemia, Hypophosphatasia), By Treatment, By Symptom, By Region, And Segment Forecasts, 2025 - 2030 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
골격 이형성증 시장 성장 및 동향:
Grand View Research, Inc.의 최신 보고서에 따르면, 세계 골격 이형성증 시장 규모는 2025년부터 2030년까지 연평균 2.0%의 CAGR을 기록하며 2030년까지 38억 5,000만 달러에 달할 것으로 예상됩니다.
특히 소아에서 이 질환의 유병률 증가와 희귀질환 치료제 채택 확대가 시장 확대에 기여했을 가능성이 높습니다.
연골무형성증은 다양한 질환 중 가장 흔한 질환입니다. 국립인간유전체연구소가 2016년 발표한 추정치에 따르면, 연골무형성증은 15,000-40,000명당 1명꼴로 발생한다고 합니다. 현재 연골무형성증에 대해 승인된 치료제는 없지만, 임상 개발 중인 치료제는 5가지가 있습니다.
연골무형성증은 FGFR3 유전자의 자연적 돌연변이로 인해 발생하며, 바이오마린의 Vosoritide는 FGFR3 경로의 억제를 표적으로 하는 연골무형성증에 대한 최초의 치료제로 현재 임상 3상 중입니다. 이 약물은 임상 3상 중이며, 2024년 시장 진입을 목표로 하고 있습니다. 클레멘티아(입센 그룹)와 리제네론(리제네론)은 다발성 골연골종 및 진행성 골화 섬유이형성증(FOP)과 같은 질환을 타깃으로 하는 다른 시장 플레이어입니다. 예측 기간 동안 이들 파이프라인 치료제가 오펀드럭으로 승인될 경우, 골격 이형성증 시장의 성장을 더욱 촉진할 것으로 보입니다.
약은 질환의 유전적 원인에 따라 다르며, XLH, 저인산효소증 등 치료 가능한 치료제는 울트라제닉스 파마슈티컬스의 크라이스비타(Crysvita)와 알렉시온 파마슈티컬스의 스트렌시크(Strensiq) 등 소수의 치료법만 승인되었습니다. Crysvita는 2018년에 FDA 승인을 받았고, Strensiq는 2015년에 승인을 받았으며, Strensiq의 매출은 2015년 1,200만 달러에서 2018년에는 4억 7,510만 달러로 증가했습니다. 이러한 희귀질환 의약품의 증가는 시장 성장의 신호로 볼 수 있습니다.
골격 이형성증 시장 보고서 하이라이트
- 저인산효소증(HPP)은 2024년 48.5%의 최대 매출 점유율을 차지하며 시장을 장악했습니다.
- 약물 요법이 시장을 주도하며 2024년 48.5%의 가장 큰 매출 점유율을 차지했습니다.
- 부갑상선 질환, 성장호르몬 요법, 척추 및 사지 절골술을 포함한 골격 기형이 2024년 20.9%의 가장 큰 매출 점유율을 차지하며 시장을 장악했습니다.
- 유럽의 골계 질환 시장은 2024년 39.4%의 가장 큰 매출 점유율을 차지하며 세계 시장을 장악했습니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 골격 이형성증 시장 변수, 동향, 범위
- 시장 계통 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 비즈니스 환경 분석
- 업계 분석 - Porter's Five Forces 분석
- PESTLE 분석
제4장 골격 이형성증 시장 : 질환 유형별 비즈니스 분석
- 질환 유형 시장 점유율, 2024년 및 2030년
- 장애 유형 부문 대시보드
- 장애 유형별 시장 규모와 예측 및 동향 분석, 2018-2030년
- X-연관 저인산증(XLH)
- 저인산증(HPP)
- 연골무형성증
- 진행성 골화성 섬유이형성증(FOP)
- 다발성 골연골종(MO)
제5장 골격 이형성증 시장 : 치료별 비즈니스 분석
- 치료 시장 점유율, 2024년과 2030년
- 치료 부문 대시보드
- 시장 규모와 예측 및 동향 분석, 치료, 2018-2030년
- 약
- 수술
제6장 골격 이형성증 시장 : 증상별 비즈니스 분석
- 증상 시장 점유율, 2024년과 2030년
- 증상 부문 대시보드
- 시장 규모와 예측 및 동향 분석, 증상별, 2018-2030년
- 골격 변형
- 치아 변형
- 기타
제7장 골격 이형성증 시장 : 지역별 추정·동향 분석
- 지역별 시장 점유율 분석, 2024년 및 2030년
- 지역 시장 대시보드
- 시장 규모, 예측 동향 분석, 2018-2030년 :
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 덴마크
- 스웨덴
- 러시아
- 아시아태평양
- 일본
- 중국
- 인도
- 한국
- 호주
- 홍콩
- 태국
- 라틴아메리카
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제8장 경쟁 상황
- 진출 기업 개요
- 기업의 시장 포지션 분석
- 기업 분류
- 전략 매핑
- 기업 개요
- BioMarin
- Amgen Inc.
- Merck KGaA
- Regeneron
- Alexion Pharmaceuticals, Inc.
- Clementia(Ipsen Group).
- AstraZeneca plc.
- Biomarin Pharmaceuticals Inc.
- Cipla Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG.
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
Skeletal Dysplasia Market Growth & Trends:
The global skeletal dysplasia market size is expected to reach USD 3.85 billion by 2030, registering a CAGR of 2.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of this condition, especially in children, and growing adoption of orphan drugs are likely to contribute to the expansion of the market.
Among different disorders, achondroplasia is the most common condition. According to estimates published by the National Human Genome Research Institute in 2016, achondroplasia occurs in 1 in 15,000-40,000 live births. Although there are no current therapies approved specifically for achondroplasia, there are five therapies under clinical development.
Genetic defects attributable to the disorder include spontaneous mutations in the FGFR3 gene. Vosoritide by BioMarin targets inhibition of the FGFR3 pathway and presents a first-in-class drug for achondroplasia. The drug is in phase III clinical trial and is expected to enter the market in 2024. Clementia (Ipsen Group) and Regeneron are other market players targeting disorders such as multiple osteochondromas and fibrodysplasia ossificans progressiva (FOP). Approval of these pipeline therapies with orphan drug status during the forecast period will further support skeletal dysplasia market growth.
The medicines vary depending on the genetic cause of the disorder and only a handful of the disorders, such as XLH and hypophosphatasia, have approved curative therapies, including Ultragenyx Pharmaceuticals' Crysvita and Alexion Pharmaceuticals' Strensiq, respectively. Crysvita received FDA approval in 2018 whereas Strensiq received approval in 2015. The sales of Strensiq increased from USD 12.0 million in 2015 to USD 475.1 million in 2018. Higher uptake of these orphan drugs signal growth of the market.
Skeletal Dysplasia Market Report Highlights:
- Hypophosphatasia (HPP) dominated the market and accounted for the largest revenue share of 48.5% in 2024 attributed to the increasing awareness and improved diagnostic capabilities, leading to more frequent diagnoses of this rare genetic disorder.
- Medications led the market and accounted for the largest revenue share of 48.5% in 2024 attributed to the advancements in drug development and increased awareness of skeletal dysplasias.
- Skeletal deformities, including parathyroid disorders, growth hormone therapies, and spinal and limb osteotomies, dominated the market and accounted for the largest revenue share of 20.9% in 2024.
- Europe skeletal dysplasia market dominated the global market and accounted for the largest revenue share of 39.4% in 2024 attributed to heightened awareness and improved diagnostic capabilities.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Disorder Type
- 1.2.2. Treatment
- 1.2.3. Symptoms
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Skeletal Dysplasia Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTLE Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Skeletal Dysplasia Market: Disorder Type Business Analysis
- 4.1. Disorder Type Market Share, 2024 & 2030
- 4.2. Disorder Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Disorder Type, 2018 to 2030 (USD Million)
- 4.4. X-linked Hypophosphatemia (XLH)
- 4.4.1. X-linked Hypophosphatemia (XLH) Market, 2018 - 2030 (USD Million)
- 4.5. Hypophosphatasia (HPP)
- 4.5.1. Hypophosphatasia (HPP) Market, 2018 - 2030 (USD Million)
- 4.6. Achondroplasia
- 4.6.1. Achondroplasia Market, 2018 - 2030 (USD Million)
- 4.7. Fibrodysplasia Ossificans Progressive (FOP)
- 4.7.1. Fibrodysplasia Ossificans Progressive (FOP) Market, 2018 - 2030 (USD Million)
- 4.8. Multiple Osteochondromas (MO)
- 4.8.1. Multiple Osteochondromas (MO) Market, 2018 - 2030 (USD Million)
Chapter 5. Skeletal Dysplasia Market: Treatment Business Analysis
- 5.1. Treatment Market Share, 2024 & 2030
- 5.2. Treatment Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
- 5.4. Medication
- 5.4.1. Medication Market, 2018 - 2030 (USD Million)
- 5.5. Surgery
- 5.5.1. Surgery Market, 2018 - 2030 (USD Million)
Chapter 6. Skeletal Dysplasia Market: Symptoms Business Analysis
- 6.1. Symptoms Market Share, 2024 & 2030
- 6.2. Symptoms Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Symptoms, 2018 to 2030 (USD Million)
- 6.4. Skeletal Deformities
- 6.4.1. Skeletal Deformities Market, 2018 - 2030 (USD Million)
- 6.5. Dental Deformities
- 6.5.1. Dental Deformities Market, 2018 - 2030 (USD Million)
- 6.6. Others
- 6.6.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Skeletal Dysplasia Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.4. North America
- 7.4.1. North America Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Regulatory Framework
- 7.4.2.3. Competitive Insights
- 7.4.2.4. U.S. Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Regulatory Framework
- 7.4.3.3. Competitive Insights
- 7.4.3.4. Canada Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Regulatory Framework
- 7.4.4.3. Competitive Insights
- 7.4.4.4. Mexico Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Regulatory Framework
- 7.5.2.3. Competitive Insights
- 7.5.2.4. UK Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Regulatory Framework
- 7.5.3.3. Competitive Insights
- 7.5.3.4. Germany Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Regulatory Framework
- 7.5.4.3. Competitive Insights
- 7.5.4.4. France Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Regulatory Framework
- 7.5.5.3. Competitive Insights
- 7.5.5.4. Italy Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Regulatory Framework
- 7.5.6.3. Competitive Insights
- 7.5.6.4. Spain Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Norway
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Regulatory Framework
- 7.5.7.3. Competitive Insights
- 7.5.7.4. Norway Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Denmark
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Regulatory Framework
- 7.5.8.3. Competitive Insights
- 7.5.8.4. Denmark Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Sweden
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Regulatory Framework
- 7.5.9.3. Competitive Insights
- 7.5.9.4. Sweden Skeletal Dysplasia Market Estimates and Forecastsasts, 2018 - 2030 (USD Million)
- 7.5.10. Russia
- 7.5.10.1. Key Country Dynamics
- 7.5.10.2. Regulatory Framework
- 7.5.10.3. Competitive Insights
- 7.5.10.4. Russia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Regulatory Framework
- 7.6.2.3. Competitive Insights
- 7.6.2.4. Japan Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Regulatory Framework
- 7.6.3.3. Competitive Insights
- 7.6.3.4. China Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Regulatory Framework
- 7.6.4.3. Competitive Insights
- 7.6.4.4. India Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. South Korea
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Regulatory Framework
- 7.6.5.3. Competitive Insights
- 7.6.5.4. South Korea Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. Australia
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Regulatory Framework
- 7.6.6.3. Competitive Insights
- 7.6.6.4. Australia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Hong Kong
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Regulatory Framework
- 7.6.7.3. Competitive Insights
- 7.6.7.4. Hong Kong Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.8. Thailand
- 7.6.8.1. Key Country Dynamics
- 7.6.8.2. Regulatory Framework
- 7.6.8.3. Competitive Insights
- 7.6.8.4. Thailand Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Regulatory Framework
- 7.7.2.3. Competitive Insights
- 7.7.2.4. Brazil Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Regulatory Framework
- 7.7.3.3. Competitive Insights
- 7.7.3.4. Argentina Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8. MEA
- 7.8.1. MEA Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Regulatory Framework
- 7.8.2.3. Competitive Insights
- 7.8.2.4. South Africa Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Regulatory Framework
- 7.8.3.3. Competitive Insights
- 7.8.3.4. Saudi Arabia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Regulatory Framework
- 7.8.4.3. Competitive Insights
- 7.8.4.4. UAE Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Regulatory Framework
- 7.8.5.3. Competitive Insights
- 7.8.5.4. Kuwait Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. BioMarin
- 8.5.1.1. Company Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Amgen Inc.
- 8.5.2.1. Company Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Merck KGaA
- 8.5.3.1. Company Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Regeneron
- 8.5.4.1. Company Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Alexion Pharmaceuticals, Inc.
- 8.5.5.1. Company Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Clementia (Ipsen Group).
- 8.5.6.1. Company Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. AstraZeneca plc.
- 8.5.7.1. Company Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Biomarin Pharmaceuticals Inc.
- 8.5.8.1. Company Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Cipla Ltd.
- 8.5.9.1. Company Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Eli Lilly and Company
- 8.5.10.1. Company Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
- 8.5.11. F. Hoffmann-La Roche AG.
- 8.5.11.1. Company Overview
- 8.5.11.2. Financial Performance
- 8.5.11.3. Product Benchmarking
- 8.5.11.4. Strategic Initiatives
- 8.5.12. Pfizer, Inc.
- 8.5.12.1. Company Overview
- 8.5.12.2. Financial Performance
- 8.5.12.3. Product Benchmarking
- 8.5.12.4. Strategic Initiatives
- 8.5.13. Teva Pharmaceutical Industries Ltd.
- 8.5.13.1. Company Overview
- 8.5.13.2. Financial Performance
- 8.5.13.3. Product Benchmarking
- 8.5.13.4. Strategic Initiatives
- 8.5.1. BioMarin
